RBM39 and cancer: Balmain and colleagues reported that KRAS4A splicing is controlled by the DCAF15/RBM39 pathway, and deletion of KRAS4A or pharmacological inhibition of RBM39 using the splicing inhibitor Indisulam leads to inhibition of cancer stem cells (Chen et al., 2021).